MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtho.2022.07.1148

Медицинская библиотека · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022

Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.

Garassino Marina C, Mazieres Julien, Reck Martin, Chouaid Christos, Bischoff Helge, Reinmuth Niels, Cove-Smith Laura, Mansy Talal, Cortinovis Diego, Migliorino Maria R, Delmonte Angelo, Sánchez José Garcia, Chara Velarde Luis Enrique, Bernabe Reyes, Paz-Ares Luis, Perez Ignacio Diaz, Trunova Nataliya, Foroutanpour Kayhan, Faivre-Finn Corinne

Клиническое исследование II фазыСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

INTRODUCTION

On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461), durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy (cCRT). Many patients are considered unsuitable for cCRT owing to concerns with tolerability. The phase 2 PACIFIC-6 trial (NCT03693300) evaluates the safety and tolerability of durvalumab after sequential CRT (sCRT).

METHODS

Patients with stage III, unresectable NSCLC and no progression after platinum-based sCRT were enrolled to receive durvalumab (1500 mg intravenously) every 4 weeks for up to 24 months. The primary end point was the incidence of grade 3 or 4 adverse events possibly related to treatment occurring within 6 months. Secondary end points included investigator-assessed progression-free survival (PFS; Response Evaluation Criteria in Solid Tumors version 1.1) and overall survival.

RESULTS

Overall, 117 patients were enrolled (59.8% with performance status >0, 65.8% aged ≥65 y, and 37.6% with stage IIIA disease). Median treatment duration was 32.0 weeks; 37.6% of patients remained on treatment at data cutoff (July 15, 2021). Grade 3 or 4 AEs occurred in 18.8% of patients. Five patients had grade 3 or 4 possibly related adverse events within 6 months (incidence: 4.3%; 95% confidence interval: 1.4-9.7), including two pneumonitis cases. Two patients (1.7%) had grade 5 AEs of any cause. Survival data maturity was limited. Median PFS was 10.9 months (95% confidence interval: 7.3-15.6), and 12-month PFS and overall survival rates were 49.6% and 84.1%, respectively.

CONCLUSIONS

Durvalumab after sCRT had a comparable safety profile with that observed with durvalumab after cCRT in PACIFIC and had encouraging preliminary efficacy in a frailer population.

Для цитирования: Garassino Marina C, Mazieres Julien, Reck Martin, Chouaid Christos, Bischoff Helge, Reinmuth Niels, Cove-Smith Laura, Mansy Talal, Cortinovis Diego, Migliorino Maria R, Delmonte Angelo, Sánchez José Garcia, Chara Velarde Luis Enrique, Bernabe Reyes, Paz-Ares Luis, Perez Ignacio Diaz, Trunova Nataliya, Foroutanpour Kayhan, Faivre-Finn Corinne. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2022. DOI: 10.1016/j.jtho.2022.07.1148.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.